Issued on behalf of Doseology Sciences Inc.
VANCOUVER — Baystreet.ca — Energy is big business, and it keeps getting bigger. Global energy drink revenue reached $38.3 billion in 2024 and is projected to hit $64.9 billion by 2034, driven by urban lifestyles and functional benefits that extend beyond basic refreshment[1]. Ready-to-drink formats hold 66% market share, with caffeinated variants leading at 76% as consumers demand convenient, measured energy without the sugar load of legacy beverages[1]. This momentum is accelerating adoption of alternative caffeine delivery methods, creating scalable pathways for Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70), BioHarvest Sciences (NASDAQ: BHST), Restart Life Sciences (CSE: HEAL) (OTC Pink: NMLSF) (FSE: HN30), Healthy Extracts (OTCQB: HYEX), and cbdMD (NYSE-A: YCBD).
Functional beverage innovation is accelerating, with multi-functional blends targeting brain health, stress relief, and sustained energy via cognitive support ingredients and plant-based compounds[2]. The segment benefits from formulation advances including microencapsulation for potency and clean-label options that enhance absorption and consumer trust[2].
Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) just launched Feed That Brain Energy Pouches in the United States through a direct-to-consumer pilot program, marking the company’s first DTC initiative in the U.S. market. Doseology specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.
The U.S. pilot represents a key milestone in Doseology’s strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation. The company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behavior.
"This U.S. pilot is a disciplined and deliberate step in Doseology’s strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology. "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."
Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation.
The company also recently appointed Larry Latowsky as Executive Chairman, bringing experience from his tenure as President and CEO of Katz Group Canada, which operated over 1,500 pharmacy locations. Latowsky cited the clarity of Doseology’s strategy and team quality as reasons for joining, stating confidence in building a durable platform and unlocking significant long-term value.
Doseology also recently granted 140,000 restricted share units and 210,000 performance share units to a director, with RSUs vesting in equal monthly increments over 36 months and PSUs vesting upon achievement of defined performance milestones.
Read this and more news for Doseology at: https://usanewsgroup.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/
In other industry developments and happenings in the market include:
BioHarvest Sciences (NASDAQ: BHST) recently launched VINIA Blood Flow Hydration, a stick-pack hydration product entering the $13 billion U.S. electrolyte drink market. Each serving delivers 23 mg of red-grape polyphenols including 6 mg of rapid-absorption Piceid resveratrol, alongside naturally sourced electrolytes: 470 mg sodium, 190 mg potassium, and 80 mg magnesium.
"I am confident that our strategy of Superior Science, Superior Efficacy and Superior Taste will allow our VINIA Blood Flow Hydration solution to disrupt this market and be a meaningful contributor to driving continued high double-digit revenue growth for the Company," said Ilan Sobel, CEO of BioHarvest Sciences.
BioHarvest’s proprietary Botanical Synthesis technology produces plant-based molecules without growing plants, enabling scalable production of its VINIA product line. The company’s cumulative VINIA sales have exceeded $50 million since the 2021 U.S. launch, with over 50,000 active subscribers and a new 100-ton-per-year production facility planned for late 2026.
Restart Life Sciences (CSE: HEAL) (OTC Pink: NMLSF) (FSE: HN30) recently announced a collaboration with the University of Manitoba’s Richardson Centre for Food Technology and Research to support scientific studies guiding product development across its functional wellness portfolio. The partnership will focus on validating formulations, optimizing ingredient functionality, and ensuring long-term stability and quality across the company’s brands.
"Partnering with RCFTR gives us access to world-class food science expertise and facilities," said Steve Loutskou, CEO of Restart Life Sciences. "This collaboration will help ensure our products meet the highest standards of efficacy, consistency, and quality as we scale our functional wellness platform."
The collaboration supports Restart Life’s expanding portfolio including BrainQ, a cognitive support product line; BrainBalls, a nutrient-dense brain wellness snack; and Holy Crap, a clean-label plant-based functional food brand acquired to extend the platform from cognitive health into gut-brain axis support.
Healthy Extracts (OTCQB: HYEX) recently announced a strategic manufacturing and commercial partnership with Gelteq Limited to accelerate the rollout of next-generation gel-based nutraceutical products. Under the agreement, Healthy Extracts will serve as the primary U.S.-based manufacturer, commercial seller, and distribution partner for new gel-format products using Gelteq’s proprietary delivery technology.
"This MoU expands our product pipeline with next-generation gel-based nutraceuticals and establishes a clear pathway to scalable U.S. manufacturing and commercial execution," said Don Swanson, CEO of Healthy Extracts.
The company reported record Q3 2025 revenue, up 23% year-over-year, with direct-to-consumer subscriptions increasing 88% and Amazon Subscribe & Save customers up 107% through the first half of 2025. Healthy Extracts develops plant-based nutraceuticals targeting heart health, hydration, and sugar management through its D2C platform and expanding retail partnerships.
cbdMD (NYSE-A: YCBD) recently reported first quarter fiscal 2026 net sales of $5.0 million, marking three consecutive quarters of sequential revenue growth with a 12% increase over the prior quarter. Wholesale revenue grew 22% year-over-year as the company expanded distribution across its diversified portfolio of CBD, functional mushroom, and hemp-derived beverage brands.
"We are encouraged by our return to sequential revenue growth and the continued stabilization of our core business," said Ronan Kennedy, CEO and CFO of cbdMD. "This quarter reflects several consecutive months of improving trends, including our strongest December and January in the past three years."
The company completed its acquisition of Bluebird Botanicals in January 2026, adding revenue, loyal customers, and GRAS-status intellectual property for full-spectrum CBD. cbdMD’s portfolio now spans its core CBD line, ATRx functional mushroom products, Herbal Oasis THC-infused social seltzers, and Paw CBD veterinary wellness products.
CONTINUED… Read this and more news for Doseology at: https://usanewsgroup.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/
CONTACT:
BAYSTREET.CA
cs@baystreet.ca
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Group, Inc. ("BAY"). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. BAY has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCE: https://usanewsgroup.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/
SOURCES CITED:
1. https://www.openpr.com/news/4403347/energy-drink-market-to-surpass-usd-64-8-billion-by-2034-driven
2. https://www.openpr.com/news/4408369/functional-beverage-market-forecast-2026-2036-global
Related Stories
